Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 7/20 | 1.00 |
| ▸ | SHBG | P04278 | 7/20 | 0.69 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.69 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.69 |
| ▸ | THRB | P10828 | 1/20 | 0.69 |
| ▸ | PGR | P06401 | 5/20 | 0.55 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.55 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.50 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.48 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.48 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.48 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25863609 | 1.00 | AR (1.00) | ARSHBGSERPINA6SLC22A1ALDH1A1 | |
| SCHEMBL29880093 | 1.00 | AR (1.00) | ARSHBGSERPINA6SLC22A1ALDH1A1 | |
| SCHEMBL5188310 | 1.00 | AR (1.00) | ARSHBGSERPINA6SLC22A1ALDH1A1 | |
| SCHEMBL24102494 | 1.00 | AR (1.00) | ARSHBGSERPINA6SLC22A1ALDH1A1 | |
| SCHEMBL14342101 | 1.00 | AR (1.00) | ARSHBGSERPINA6SLC22A1ALDH1A1 | |
| SCHEMBL24103284 | 1.00 | AR (1.00) | ARSHBGSERPINA6SLC22A1ALDH1A1 | |
| SCHEMBL5026430 | 1.00 | AR (1.00) | ARSHBGSERPINA6SLC22A1ALDH1A1 | |
| SCHEMBL24103286 | 1.00 | AR (1.00) | ARSHBGSERPINA6SLC22A1ALDH1A1 | |
| SCHEMBL223290 | 1.00 | AR (1.00) | ARSHBGSERPINA6SLC22A1ALDH1A1 | |
| SCHEMBL199806 | 1.00 | AR (1.00) | ARSHBGSERPINA6SLC22A1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 704 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3441089-B1 | TREATMENT METHODS USING ADENOVIRUS | VASCULAR BIOGENICS LTD (IL) | 2022-12-14 | — | — | EP | claimed |
| EP-3191114-B1 | OCCIDIOFUNGIN FORMULATIONS AND USES THEREOF | UNIV MISSISSIPPI STATE (US) | 2021-03-03 | — | — | EP | claimed |
| EP-2908865-B1 | ADENOVIRUS EXPRESSING A FAS-CHIMERA AND USE THEREOF IN CANCER TREATMENT METHODS | VASCULAR BIOGENICS LTD (IL) | 2018-10-03 | — | — | EP | claimed |
| EP-2923703-B1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | NANTBIO INC (US) | 2018-09-19 | — | — | EP | claimed |
| EP-3368081-A1 | TREATMENT OF CANCER WITH COMBINATIONS OF RXR AGONISTS AND THYROID HORMONES | IO Therapeutics, Inc. (US) | 2018-09-05 | — | — | EP | claimed |
| EP-3124481-B1 | ANDROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS INC (US) | 2018-03-28 | — | — | EP | claimed |
| WO-2017075612-A1 | TREATMENT OF CANCER WITH COMBINATIONS OF RXR AGONISTS AND THYROID HORMONES | Io Therapeutics, Inc. (US) | 2017-05-04 | — | — | WO | claimed |
| EP-2358697-B1 | ISOINDOLINE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER. | CELGENE CORP (US) | 2015-10-21 | — | — | EP | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| EP-2425840-B1 | Triazine derivatives and their therapeutical applications | ABRAXIS BIOSCIENCE INC (US) | 2015-04-08 | — | — | EP | claimed |
| EP-2649998-B1 | Prolyl hydroxylase inhibitors | AERPIO THERAPEUTICS INC (US) | 2015-03-04 | — | — | EP | claimed |
| CN-104244968-A | PH20 polypeptide variants, formulations, and uses thereof | HALOZYME INC | 2014-12-24 | — | — | CN | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| US-20080292585-A1 | Azonafide Derivatives, Methods for Their Production and Pharmaceutical Compositions Therefrom | UNIBIOSCREEN S.A. (BE) | 2008-11-27 | — | — | US | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20040223983-A1 | Pharmaceutical preparations, use of these preparations and process for increasing the biovailability of pharmaceutical substances to be administered perorally | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-11-11 | — | — | US | claimed |
| WO-2026106969-A1 | NOVEL INHIBITORS OF INTERLEUKIN RECEPTOR- ASSOCIATED KINASE | UNIVERSITY OF ROCHESTER (US) | 2026-05-21 | — | — | WO | disclosed |
| WO-1999030690-A1 | ORAL DELIVERY FORMULATION | AXIA THERAPEUTICS, INC. (US) | 1999-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080292585-A1 | Azonafide Derivatives, Methods for Their Production and Pharmaceutical Compositions Therefrom | AADAC, NOTUM, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | AR 742/4885SHBG 2047/4885SERPINA6 4500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.